Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Non-Invasive Buccal Swab Gene Testing for Skin Cancer Risk

Moy L, Lyons AB, Fox W, Glicksman MA, Moy R, Tung R.

J Drugs Dermatol. 2019 May 1;18(5):448-453.

PMID:
31141850
2.

Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy.

Glicksman MA.

Clin Ther. 2018 Jul;40(7):1060-1065. doi: 10.1016/j.clinthera.2018.06.004. Epub 2018 Jul 23.

PMID:
30049501
3.

Inhibition of Protein-Protein Interactions: Cell-Based Assays.

Wade M, Méndez J, Coussens NP, Arkin MR, Glicksman MA.

In: Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2017 Nov 20.

4.

Optimization of a series of heterocycles as survival motor neuron gene transcription enhancers.

Choi S, Calder AN, Miller EH, Anderson KP, Fiejtek DK, Rietz A, Li H, Cherry JJ, Quist KM, Xing X, Glicksman MA, Cuny GD, Lorson CL, Androphy EA, Hodgetts KJ.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5144-5148. doi: 10.1016/j.bmcl.2017.10.066. Epub 2017 Oct 26.

5.

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR.

Science. 2017 Sep 1;357(6354):891-898. doi: 10.1126/science.aaf3934.

6.

Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.

Rietz A, Li H, Quist KM, Cherry JJ, Lorson CL, Burnett BG, Kern NL, Calder AN, Fritsche M, Lusic H, Boaler PJ, Choi S, Xing X, Glicksman MA, Cuny GD, Androphy EJ, Hodgetts KJ.

J Med Chem. 2017 Jun 8;60(11):4594-4610. doi: 10.1021/acs.jmedchem.6b01885. Epub 2017 May 19.

7.

Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation.

Yang Z, Concannon J, Ng KS, Seyb K, Mortensen LJ, Ranganath S, Gu F, Levy O, Tong Z, Martyn K, Zhao W, Lin CP, Glicksman MA, Karp JM.

Sci Rep. 2016 Jul 26;6:30263. doi: 10.1038/srep30263.

8.

Tackling reproducibility in academic preclinical drug discovery.

Frye SV, Arkin MR, Arrowsmith CH, Conn PJ, Glicksman MA, Hull-Ryde EA, Slusher BS.

Nat Rev Drug Discov. 2015 Nov;14(11):733-4. doi: 10.1038/nrd4737. Epub 2015 Sep 21.

PMID:
26388229
9.

Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors.

Mukherjee A, Syeb K, Concannon J, Callegari K, Soto C, Glicksman MA.

PLoS One. 2015 Jul 15;10(7):e0131297. doi: 10.1371/journal.pone.0131297. eCollection 2015.

10.

Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis.

Manocha GD, Puig KL, Austin SA, Seyb K, Glicksman MA, Combs CK.

PLoS One. 2015 Jul 10;10(7):e0132604. doi: 10.1371/journal.pone.0132604. eCollection 2015.

11.

Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease.

Takahashi K, Kong Q, Lin Y, Stouffer N, Schulte DA, Lai L, Liu Q, Chang LC, Dominguez S, Xing X, Cuny GD, Hodgetts KJ, Glicksman MA, Lin CL.

J Exp Med. 2015 Mar 9;212(3):319-32. doi: 10.1084/jem.20140413. Epub 2015 Feb 23.

12.

A loss of FUS/TLS function leads to impaired cellular proliferation.

Ward CL, Boggio KJ, Johnson BN, Boyd JB, Douthwright S, Shaffer SA, Landers JE, Glicksman MA, Bosco DA.

Cell Death Dis. 2014 Dec 11;5:e1572. doi: 10.1038/cddis.2014.508.

13.

Inhibition of large T antigen ATPase activity as a potential strategy to develop anti-polyomavirus JC drugs.

Randhawa P, Zeng G, Bueno M, Salgarkar A, Lesniak A, Isse K, Seyb K, Perry A, Charles I, Hustus C, Huang M, Smith M, Glicksman MA.

Antiviral Res. 2014 Dec;112:113-9. doi: 10.1016/j.antiviral.2014.10.004. Epub 2014 Oct 15.

14.

Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease.

Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, Ghosh D, Kanyo J, Zhang Y, Seyb K, Ononenyi C, Foscue E, Anderson GM, Gresack J, Cuny GD, Glicksman MA, Greengard P, Lam TT, Tautz L, Nairn AC, Ellman JA, Lombroso PJ.

PLoS Biol. 2014 Aug 5;12(8):e1001923. doi: 10.1371/journal.pbio.1001923. eCollection 2014 Aug.

15.

A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.

Dusonchet J, Li H, Guillily M, Liu M, Stafa K, Derada Troletti C, Boon JY, Saha S, Glauser L, Mamais A, Citro A, Youmans KL, Liu L, Schneider BL, Aebischer P, Yue Z, Bandopadhyay R, Glicksman MA, Moore DJ, Collins JJ, Wolozin B.

Hum Mol Genet. 2014 Sep 15;23(18):4887-905. doi: 10.1093/hmg/ddu202. Epub 2014 May 2.

16.

The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.

Ray S, Bender S, Kang S, Lin R, Glicksman MA, Liu M.

J Biol Chem. 2014 May 9;289(19):13042-53. doi: 10.1074/jbc.M113.537811. Epub 2014 Apr 2.

17.

Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors.

Pytel D, Seyb K, Liu M, Ray SS, Concannon J, Huang M, Cuny GD, Diehl JA, Glicksman MA.

J Biomol Screen. 2014 Aug;19(7):1024-34. doi: 10.1177/1087057114525853. Epub 2014 Mar 5.

18.

Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection.

Kong Q, Chang LC, Takahashi K, Liu Q, Schulte DA, Lai L, Ibabao B, Lin Y, Stouffer N, Das Mukhopadhyay C, Xing X, Seyb KI, Cuny GD, Glicksman MA, Lin CL.

J Clin Invest. 2014 Mar;124(3):1255-67. doi: 10.1172/JCI66163. Epub 2014 Feb 24.

19.

The 14th International Conference on Alzheimer's Drug Discovery, 9 - 10 September 2013, in Jersey City, New Jersey.

Glicksman MA.

Expert Opin Drug Discov. 2014 Feb;9(2):215-20. doi: 10.1517/17460441.2014.877441.

PMID:
24444088
20.

A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.

Boyd JD, Lee P, Feiler MS, Zauur N, Liu M, Concannon J, Ebata A, Wolozin B, Glicksman MA.

J Biomol Screen. 2014 Jan;19(1):44-56. doi: 10.1177/1087057113501553. Epub 2013 Sep 9.

21.

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ.

EMBO Mol Med. 2013 Jul;5(7):1103-18. doi: 10.1002/emmm.201202305. Epub 2013 Jun 5.

22.

Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats.

Arkin MR, Glicksman MA, Fu H, Havel JJ, Du Y.

In: Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 Mar 18 [updated 2012 Oct 1].

23.

Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

Lin CL, Kong Q, Cuny GD, Glicksman MA.

Future Med Chem. 2012 Sep;4(13):1689-700. doi: 10.4155/fmc.12.122.

24.

Small-molecule Klotho enhancers as novel treatment of neurodegeneration.

Abraham CR, Chen C, Cuny GD, Glicksman MA, Zeldich E.

Future Med Chem. 2012 Sep;4(13):1671-9. doi: 10.4155/fmc.12.134.

25.

Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein dimerization.

So PP, Zeldich E, Seyb KI, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glicksman MA, Abraham CR.

Am J Neurodegener Dis. 2012;1(1):75-87.

26.

A high-throughput screen to identify inhibitors of SOD1 transcription.

Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, Ivinson AJ, Glicksman MA, Ferrante RJ, Matson W, Matson S, Brown RH Jr.

Front Biosci (Elite Ed). 2012 Jun 1;4:2701-8.

27.

The preclinical discovery of amyotrophic lateral sclerosis drugs.

Glicksman MA.

Expert Opin Drug Discov. 2011 Nov;6(11):1127-38. doi: 10.1517/17460441.2011.628654. Epub 2011 Oct 25.

28.

Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.

Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):2015-9. doi: 10.1016/j.bmcl.2012.01.028. Epub 2012 Jan 28.

29.

A new means to identify type 3 secreted effectors: functionally interchangeable class IB chaperones recognize a conserved sequence.

Costa SC, Schmitz AM, Jahufar FF, Boyd JD, Cho MY, Glicksman MA, Lesser CF.

MBio. 2012 Feb 14;3(1). pii: e00243-11. doi: 10.1128/mBio.00243-11. Print 2012.

30.

Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay.

Cherry JJ, Evans MC, Ni J, Cuny GD, Glicksman MA, Androphy EJ.

J Biomol Screen. 2012 Apr;17(4):481-95. doi: 10.1177/1087057111431605. Epub 2012 Jan 10.

31.

A high-throughput screening method for small-molecule inhibitors of the aberrant mutant SOD1 and dynein complex interaction.

Tang X, Seyb KI, Huang M, Schuman ER, Shi P, Zhu H, Glicksman MA.

J Biomol Screen. 2012 Mar;17(3):314-26. doi: 10.1177/1087057111429595. Epub 2011 Dec 1.

32.

Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, Gerber SA, Cuny GD, Glicksman MA.

Biochemistry. 2011 Nov 1;50(43):9399-408. doi: 10.1021/bi201173d. Epub 2011 Oct 7.

33.

Identification of novel small molecules that elevate Klotho expression.

King GD, Chen C, Huang MM, Zeldich E, Brazee PL, Schuman ER, Robin M, Cuny GD, Glicksman MA, Abraham CR.

Biochem J. 2012 Jan 1;441(1):453-61. doi: 10.1042/BJ20101909.

34.

Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators.

Xing X, Chang LC, Kong Q, Colton CK, Lai L, Glicksman MA, Lin CL, Cuny GD.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5774-7. doi: 10.1016/j.bmcl.2011.08.009. Epub 2011 Aug 8.

35.

Dehydro-alpha-lapachone, a plant product with antivascular activity.

Garkavtsev I, Chauhan VP, Wong HK, Mukhopadhyay A, Glicksman MA, Peterson RT, Jain RK.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11596-601. doi: 10.1073/pnas.1104225108. Epub 2011 Jun 27.

36.

Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production.

Shishova EY, Stoll JM, Ersoy BA, Shrestha S, Scapa EF, Li Y, Niepel MW, Su Y, Jelicks LA, Stahl GL, Glicksman MA, Gutierrez-Juarez R, Cuny GD, Cohen DE.

Hepatology. 2011 Aug;54(2):664-74. doi: 10.1002/hep.24393. Epub 2011 Jun 23.

37.

Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.

Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG.

Ann Neurol. 2011 Jun;69(6):940-53. doi: 10.1002/ana.22400. Epub 2011 Apr 6.

PMID:
21472771
38.

Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.

Cuny GD, Robin M, Ulyanova NP, Patnaik D, Pique V, Casano G, Liu JF, Lin X, Xian J, Glicksman MA, Stein RL, Higgins JM.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3491-4.

39.

Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.

Liu M, Poulose S, Schuman E, Zaitsev AD, Dobson B, Auerbach K, Seyb K, Cuny GD, Glicksman MA, Stein RL, Yue Z.

Anal Biochem. 2010 Sep 15;404(2):186-92. doi: 10.1016/j.ab.2010.05.033. Epub 2010 Jun 2.

40.

Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.

Colton CK, Kong Q, Lai L, Zhu MX, Seyb KI, Cuny GD, Xian J, Glicksman MA, Lin CL.

J Biomol Screen. 2010 Jul;15(6):653-62. doi: 10.1177/1087057110370998. Epub 2010 May 27.

41.

Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect.

Liu M, Girma E, Glicksman MA, Stein RL.

Biochemistry. 2010 Jun 15;49(23):4921-9. doi: 10.1021/bi100244j.

42.

A high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-coupled receptor GPR54.

Kuohung W, Burnett M, Mukhtyar D, Schuman E, Ni J, Crowley WF, Glicksman MA, Kaiser UB.

J Biomol Screen. 2010 Jun;15(5):508-17. doi: 10.1177/1087057110369701. Epub 2010 May 10.

43.

Kinetic-based high-throughput screening assay to discover novel classes of macrophage migration inhibitory factor inhibitors.

Ouertatani-Sakouhi H, Liu M, El-Turk F, Cuny GD, Glicksman MA, Lashuel HA.

J Biomol Screen. 2010 Apr;15(4):347-58. doi: 10.1177/1087057110363825. Epub 2010 Mar 15.

PMID:
20231420
44.

Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.

Liu M, Dobson B, Glicksman MA, Yue Z, Stein RL.

Biochemistry. 2010 Mar 9;49(9):2008-17. doi: 10.1021/bi901851y.

45.

Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.

Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6122-6. doi: 10.1016/j.bmcl.2009.09.010. Epub 2009 Sep 9.

46.

Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay.

Patnaik D, Jun Xian, Glicksman MA, Cuny GD, Stein RL, Higgins JM.

J Biomol Screen. 2008 Dec;13(10):1025-34. doi: 10.1177/1087057108326081. Epub 2008 Oct 31.

47.

Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform.

Seyb KI, Schuman ER, Ni J, Huang MM, Michaelis ML, Glicksman MA.

J Biomol Screen. 2008 Oct;13(9):870-8. doi: 10.1177/1087057108323909. Epub 2008 Sep 23.

48.

Small-molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by high-throughput screening.

Wagle N, Xian J, Shishova EY, Wei J, Glicksman MA, Cuny GD, Stein RL, Cohen DE.

Anal Biochem. 2008 Dec 1;383(1):85-92. doi: 10.1016/j.ab.2008.07.039. Epub 2008 Aug 12.

49.

Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.

Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, Auerbach K, Stein RL.

Biochemistry. 2008 Aug 12;47(32):8367-77. doi: 10.1021/bi800732v. Epub 2008 Jul 18.

PMID:
18636751
50.

New approaches to the discovery of cdk5 inhibitors.

Glicksman MA, Cuny GD, Liu M, Dobson B, Auerbach K, Stein RL, Kosik KS.

Curr Alzheimer Res. 2007 Dec;4(5):547-9. Review.

PMID:
18220519

Supplemental Content

Loading ...
Support Center